Tri-Counties will get 1,000 new vehicle charging stations
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Impact raises $150M, plans 2022 IPO
Note: This article was updated July 15 to include an interview with Impact’s CEO. Impact Technologies, a cloud software company based in Santa Barbara, announced a $150 million round of venture capital funding on July 13 and is planning an initial public offering in early 2022, CEO David Yovanno told the Business Times. With the Read More →
Income up at Community Bank of Santa Maria
Community Bank of Santa Maria saw its net income rise more than 35% for the most recent quarter as total assets, deposits and net loans all increased. In a July 13 earnings statement, the bank reported net income of $1.44 million for the quarter ended June 30, 36.1% higher than the same quarter of the Read More →
Real Estate: Simi Valley industrial property sold for $20M
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
30 years of South Coast Deli: Santa Barbara tech scene boosts local sandwich shop
When Jim St. John launched South Coast Deli in Carpinteria 30 years ago, his goal was to bring an edgier menu to the region and as a result, he added a scoop of culinary innovation to an emerging technology hub. Basil mayo, cranberry-thyme cream cheese and a killer garlic dressing for Caesar sandwiches struck a Read More →
FDA gives Amgen priority review for asthma treatment
Thousand Oaks-based Amgen received a priority review for tezepelumab, a treatment for asthma, from the U.S. Food and Drug Administration, the biotech giant announced July 7. According to Amgen, tezepelumab is the first and only biologic to consistently and significantly reduce asthma exacerbations in a broad population of clients in phase 2 and 3 trials. Read More →
Santa Barbara tourism comeback underway
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
